{
    "symbol": "ATHX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 23:07:03",
    "content": " Second, I'll review how the restructuring process results in a leaner, more agile Athersys and how it provides a roadmap for deploying our wealth, our preclinical data to heighten MultiStem's potential that could drive new opportunities through a business development strategy that delivers derisked accretive shareholder value. This is encouraging momentum that's being driven primarily from news of the TREASURE study results in Japan, increased levels of engagement with participating stroke centers and the addition of new trial sites that we've been activating since the beginning of the year, such as in Australia, Taiwan and key stroke centers across Europe."
}